HomeCompareCTXRW vs VICI

CTXRW vs VICI: Dividend Comparison 2026

CTXRW yields 1387.93% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908155.11M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — CTXRW vs VICI

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTXRW pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, CTXRW beats the other by $258,266,920,676,179.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + VICI for your $10,000?

CTXRW: 50%VICI: 50%
100% VICI50/50100% CTXRW
Portfolio after 10yr
$173454078.54M
Annual income
$151,921,718,668,072.88/yr
Blended yield
87.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CTXRW
No analyst data
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
VICI buys
0
No recent congressional trades found for CTXRW or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWVICI
Forward yield1387.93%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$346908156.10M$988.8K
Annual income after 10y$303,843,436,712,884.44$623,261.32
Total dividends collected$343747776.19M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CTXRW vs VICI ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$149,493$138,792.51$11,368$948.43+$138.1KCTXRW
2$2,099,063$1,939,106.48$13,339$1,493.16+$2.09MCTXRW
3$27,692,262$25,446,263.94$16,326$2,426.21+$27.68MCTXRW
4$343,373,046$313,742,325.46$21,123$4,112.15+$343.35MCTXRW
5$4,003,185,043$3,635,775,884.26$29,379$7,368.23+$4003.16MCTXRW
6$43,897,781,482$39,614,373,485.65$44,804$14,191.64+$43897.74MCTXRW
7$452,951,824,425$405,981,198,239.62$76,658$29,972.12+$452951.75MCTXRW
8$4,399,656,810,870$3,914,998,358,735.43$150,894$71,015.81+$4399656.66MCTXRW
9$40,247,401,294,059$35,539,768,506,427.31$350,814$193,582.47+$40247400.94MCTXRW
10$346,908,156,097,527$303,843,436,712,884.44$988,809$623,261.32+$346908155.11MCTXRW

CTXRW vs VICI: Complete Analysis 2026

CTXRWStock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CTXRW vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs OCTXRW vs KOCTXRW vs MAINCTXRW vs NNNCTXRW vs EPRTCTXRW vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.